Treatment and Prevention of Alzheimer’s disease(AD)

NEUROSTEM^® an allogeneic umbilical cord blood-derived mesenchymal stem cell product, is under development for the treatment of Alzheimer’s Disease. Phase 2a clinical trial has been completed as of December 2019 after successfully completing the Phase 1 clinical trial in Korea.

Before and after the administration of NEUROSTEM^® (animal experiments)

NEUROSTEM^® Mechanism of Action video

The accumulation of β-amyloid in the brain, which causes Alzheimer-type dementia, induces learning and memory disorder by damaging the nerve cells. Once NEUROSTEM^® is administrated to the patient’s brain with Alzheimer-type dementia, the umbilical cord blood-derived mesenchymal stem cells migrate towards the injury signals within the damaged brain and secrete proteins which stimulate microglia cells. The stimulated microglia cells promote the degradation of β-amyloid by secreting β-amyloid degrading enzymes.